Highbridge Capital Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Highbridge Capital Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,283,979	Closed	-$2.91M	–	413
2023 Q3	$2.91M	Buy	+2,283,979	New	+$1.99M	0.12%	91

Highbridge Capital Management's ZYNE Position: Q4 2023 in Review

Highbridge Capital Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 2,283,979 shares — an estimated $2.91M sold.

Highbridge Capital Management first reported a position in ZYNE in Q3 2023 and held it in 1 quarter. The position peaked at $2.91M in Q3 2023. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.

Highbridge Capital Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
Highbridge Capital Management sold 2,283,979 Zynerba Pharmaceuticals, Inc shares in Q4 2023, an estimated $2.91M.
Highbridge Capital Management first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2023 and held it in 1 quarter.
Highbridge Capital Management's Zynerba Pharmaceuticals, Inc position peaked at $2.91M in Q3 2023.
0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.

Based on Highbridge Capital Management's 13F filing for Q4 2023, filed 12 Feb 2024.